This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Armengol, G. Articles by Ramón y Cajal, S. Search for Related Content PubMed PubMed Citation Articles by Armengol, G. Articles by Ramón y Cajal, S. Related Collections Therapeutics and Targets Therapeutics and Targets: Identification, Validation, and Markers

4E-Binding Protein 1: A Key Molecular "Funnel Factor" in Human Cancer with Clinical Implications

Departments of ¹ Pathology and ² Oncology, Vall d'Hebron University Hospital, Barcelona, Spain

Requests for reprints: Santiago Ramón y Cajal, Department of Pathology, Vall d'Hebron University Hospital, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain. Phone: 34-932746824; Fax: 34-934894015; E-mail: sramon{at}vhebron.net.

In an attempt to identify molecules that clearly reflect the oncogenic role of cell signaling pathways in human tumors, we propose a concept we term "funnel factor", a factor where several oncogenic signals converge and drive the proliferative signal downstream. In studies done in various tumor types, the expression of key cell signaling factors, including Her1 and Her2 growth factor receptors, as well as the RAS-RAF-mitogen-activated protein kinase and the phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathways was correlated with the associated clinicopathologic characteristics of these tumors. The downstream factors p70, S6, 4E-binding protein 1 (4E-BP1), and eukaryotic translation initiation factor 4E, which play a critical role in the control of protein synthesis, survival, and cell growth, were also analyzed. We found that phosphorylated 4E-BP1 (p-4E-BP1) expression in breast, ovary, and prostate tumors is associated with malignant progression and an adverse prognosis regardless of the upstream oncogenic alterations. Thus, p-4E-BP1 seems to act as a funnel factor for an essential oncogenic capability of tumor cells, self-sufficiency in growth signals, and could be a highly relevant molecular marker of malignant potential. Further investigation into this concept may identify additional funnel factors in the oncogenic pathways and provide potential therapeutic targets. [Cancer Res 2007;67(16):7551–5]

This article has been cited by other articles:

				S. Y. Ko, H. Guo, N. Barengo, and H. Naora Inhibition of Ovarian Cancer Growth by a Tumor-Targeting Peptide That Binds Eukaryotic Translation Initiation Factor 4E Clin. Cancer Res., July 1, 2009; 15(13): 4336 - 4347. [Abstract] [Full Text] [PDF]

				K. L.B. Borden Tissue Targeting in Cancer: eIF4E's Tale Clin. Cancer Res., July 1, 2009; 15(13): 4254 - 4255. [Abstract] [Full Text] [PDF]

				C.-J. Lin, R. Sukarieh, and J. Pelletier Silibinin inhibits translation initiation: implications for anticancer therapy Mol. Cancer Ther., June 1, 2009; 8(6): 1606 - 1612. [Abstract] [Full Text] [PDF]

				O. C. Rodriguez, E. W. Lai, S. Vissapragada, C. Cromelin, M. Avetian, P. Salinas, H. Ramos, B. Kallakury, M. Casimiro, M. P. Lisanti, et al. A Reduction in Pten Tumor Suppressor Activity Promotes ErbB-2-Induced Mouse Prostate Adenocarcinoma Formation through the Activation of Signaling Cascades Downstream of PDK1 Am. J. Pathol., June 1, 2009; 174(6): 2051 - 2060. [Abstract] [Full Text] [PDF]

				A. Artero-Castro, F. B. Callejas, J. Castellvi, H. Kondoh, A. Carnero, P. J. Fernandez-Marcos, M. Serrano, S. Ramon y Cajal, and M. E. Lleonart Cold-Inducible RNA-Binding Protein Bypasses Replicative Senescence in Primary Cells through Extracellular Signal-Regulated Kinase 1 and 2 Activation Mol. Cell. Biol., April 1, 2009; 29(7): 1855 - 1868. [Abstract] [Full Text] [PDF]

				N. T. Ihle, R. Lemos Jr., P. Wipf, A. Yacoub, C. Mitchell, D. Siwak, G. B. Mills, P. Dent, D. L. Kirkpatrick, and G. Powis Mutations in the Phosphatidylinositol-3-Kinase Pathway Predict for Antitumor Activity of the Inhibitor PX-866 whereas Oncogenic Ras Is a Dominant Predictor for Resistance Cancer Res., January 1, 2009; 69(1): 143 - 150. [Abstract] [Full Text] [PDF]

				A. Y. Choo, S.-O. Yoon, S. G. Kim, P. P. Roux, and J. Blenis Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation PNAS, November 11, 2008; 105(45): 17414 - 17419. [Abstract] [Full Text] [PDF]

				L. Rong, M. Livingstone, R. Sukarieh, E. Petroulakis, A.-C. Gingras, K. Crosby, B. Smith, R. D. Polakiewicz, J. Pelletier, M. A. Ferraiuolo, et al. Control of eIF4E cellular localization by eIF4E-binding proteins, 4E-BPs RNA, July 1, 2008; 14(7): 1318 - 1327. [Abstract] [Full Text] [PDF]

				S. Pervin, A. H. Tran, S. Zekavati, J. M. Fukuto, R. Singh, and G. Chaudhuri Increased Susceptibility of Breast Cancer Cells to Stress Mediated Inhibition of Protein Synthesis Cancer Res., June 15, 2008; 68(12): 4862 - 4874. [Abstract] [Full Text] [PDF]

				J. R. Graff, B. W. Konicek, J. H. Carter, and E. G. Marcusson Targeting the Eukaryotic Translation Initiation Factor 4E for Cancer Therapy Cancer Res., February 1, 2008; 68(3): 631 - 634. [Abstract] [Full Text] [PDF]

				G. C. Prendergast "Generalized" versus "individualized" medicine: Therapeutic and prognostic opportunities Cancer Reviews Online Content, August 31, 2007; 2007(6): 11 - 11. [Full Text] [PDF]